share_log

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Shutterly Andrew

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Shutterly Andrew

Altimmune | 4:持股變動聲明-高管 Shutterly Andrew
美股SEC公告 ·  08/01 17:51
Moomoo AI 已提取核心訊息
Andrew Shutterly, Acting Chief Financial Officer of Altimmune, Inc., completed a purchase of 1,259 shares of common stock on July 31, 2024. The transaction was carried out at a price of $5.41 per share, resulting in a total investment of approximately $6,811.99. Following this acquisition, Shutterly's direct holdings in the company increased to 11,372 shares of common stock. The transaction reflects a direct ownership interest and is reported as a grant, award, or other acquisition in line with the transaction code 'A'.
Andrew Shutterly, Acting Chief Financial Officer of Altimmune, Inc., completed a purchase of 1,259 shares of common stock on July 31, 2024. The transaction was carried out at a price of $5.41 per share, resulting in a total investment of approximately $6,811.99. Following this acquisition, Shutterly's direct holdings in the company increased to 11,372 shares of common stock. The transaction reflects a direct ownership interest and is reported as a grant, award, or other acquisition in line with the transaction code 'A'.
Altimmune公司臨時代碼致富金融執行首席財務官Andrew Shutterly於2024年7月31日購買了1,259股普通股。交易價格爲每股5.41美元,總投資約6,811.99美元。此次收購後,Shutterly在該公司的直接持股數量增加至11,372股普通股。該交易反映出直接持有權益,並根據交易代碼“A”報告爲授權、獎勵或其他收購。
Altimmune公司臨時代碼致富金融執行首席財務官Andrew Shutterly於2024年7月31日購買了1,259股普通股。交易價格爲每股5.41美元,總投資約6,811.99美元。此次收購後,Shutterly在該公司的直接持股數量增加至11,372股普通股。該交易反映出直接持有權益,並根據交易代碼“A”報告爲授權、獎勵或其他收購。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息